2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006050460v1 17/12/3458    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dember, L. M. Search for Related Content PubMed PubMed Citation Articles by Dember, L. M.

Amyloidosis-Associated Kidney Disease

Renal Section and Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, Massachusetts

Address correspondence to: Dr. Laura M. Dember, Renal Section, Boston University School of Medicine, EBRC 504, 650 Albany Street, Boston, MA 02118. Phone: 617-638-7331; Fax: 617-859-7549; E-mail: ldember{at}bu.edu

The amyloidoses are a group of disorders in which soluble proteins aggregate and deposit extracellularly in tissues as insoluble fibrils, causing progressive organ dysfunction. The kidney is one of the most frequent sites of amyloid deposition in AL, AA, and several of the hereditary amyloidoses. Amyloid fibril formation begins with the misfolding of an amyloidogenic precursor protein. The misfolded variants self-aggregate in a highly ordered manner, generating protofilaments that interact to form fibrils. The fibrils have a characteristic appearance by electron microscopy and generate birefringence under polarized light when stained with Congo red dye. Advances in elucidating the mechanisms of amyloid fibril formation, tissue deposition, and tissue injury have led to new and more aggressive treatment approaches for these disorders. This article reviews the pathogenesis, diagnosis, clinical manifestations, and treatment of the amyloidoses, focusing heavily on the renal aspects of each of these areas.

This article has been cited by other articles:

				A. O'Riordan, N. Dutt, H. Cairns, M. Rela, J. G. O'Grady, N. Heaton, and B. M. Hendry Renal biopsy in liver transplant recipients Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2276 - 2282. [Abstract] [Full Text] [PDF]

				Y. Cao, Y. Zhang, S. Wang, M. Zhao, and W. Zou Simultaneous occurrence of hepatitis C virus-associated glomerulonephritis and AL amyloidosis Nephrol. Dial. Transplant., June 25, 2009; (2009) gfp296v1. [Abstract] [Full Text] [PDF]

				L. M. Dember Modern Treatment of Amyloidosis: Unresolved Questions J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472. [Abstract] [Full Text] [PDF]

				K. P. Choe and K. Strange Genome-wide RNAi screen and in vivo protein aggregation reporters identify degradation of damaged proteins as an essential hypertonic stress response Am J Physiol Cell Physiol, December 1, 2008; 295(6): C1488 - C1498. [Abstract] [Full Text] [PDF]

				G. Bollee, B. Guery, D. Joly, R. Snanoudj, B. Terrier, M. Allouache, L. Mercadal, M.-N. Peraldi, B. Viron, C. Fumeron, et al. Presentation and Outcome of Patients with Systemic Amyloidosis Undergoing Dialysis Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 375 - 381. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673